Allarity Therapeutics, Inc. (ALLR )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol ALLR
- Company Allarity Therapeutics, Inc.
- Price $1.66
- Changes Percentage 16.08
- Change 0.23
- Day Low $1.4
- Day High $1.69
- Year High $666
- Year Low $1.36
- Market Cap $2,344,999
- Price Avg 50 EMA (D) $3.54
- Price Avg 200 EMA (D) $93.74
- Exchange NASDAQ
- Volume 535,718
- Average Volume 450,641
- Open $1.41
- Previous Close $1.43
- EPS -10.98
- PE -0.15
- Earnings Announcement 2024-11-12 12:00:00
- Shares Outstanding $1,412,650
Company brief: ALLARITY THERAPEUTICS, INC. (ALLR )
- Healthcare
- Biotechnology
- Mr. Thomas H. Jensen
- https://www.allarity.com
- US
- N/A
- 12-21-2021
- US0167443029
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.
ALLR Corporation News
ALLR Investors Have Opportunity to Lead Allarity Therapeutics, Inc. Securities Fraud Lawsuit
prnewswire.com -- NEW YORK , Oct. 15, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Allarity Therapeutics, Inc. (NASDAQ: ALLR) between May 17, 2022 ...
Allarity Therapeutics Inc Is Being Sued For Violating Securities Laws And Affected Investors Are Urged To Contact The Schall Law Firm
accesswire.com -- LOS ANGELES, CA / ACCESSWIRE / October 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Allarity Therapeutics, Inc. ("...
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Allarity Therapeutics, Inc. Inc. of Class Action Lawsuit and Upcoming Deadlines - ALLR
accesswire.com -- NEW YORK, NY / ACCESSWIRE / October 15, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR) and ce...
ALLR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Investors of Allarity Therapeutics, Inc. to Contact the Firm Today!
accesswire.com -- NEW YORK, NY / ACCESSWIRE / October 15, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Allarity Ther...
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Allarity Therapeutics, Inc. (ALLR)
globenewswire.com -- LOS ANGELES, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming November 12, 2024 deadline to file a lead plaintiff motion in the class action...
The Schall Law Firm Encourages Shareholder Participation In A Securities Fraud Case Against Allarity Therapeutics, Inc.
accesswire.com -- LOS ANGELES, CA / ACCESSWIRE / October 14, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Allarity Therapeutics, Inc. ("...
ALLR Stockholders Have Opportunity to Lead Allarity Therapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today!
accesswire.com -- NEW YORK, NY / ACCESSWIRE / October 14, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Allarity Ther...
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Allarity Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ALLR
globenewswire.com -- NEW YORK, Oct. 13, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Allarity Therapeutics, Inc. (NASDAQ: ALLR) between May 17, 2022 ...
ALLR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Allarity Therapeutics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit!
accesswire.com -- NEW YORK, NY / ACCESSWIRE / October 13, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Allarity Ther...
ALLR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Allarity Therapeutics, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit!
accesswire.com -- NEW YORK, NY / ACCESSWIRE / October 11, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Allarity Ther...